Figure 1.
Cellular pathway of thymidine with the interaction of pemetrexed indicated.
18F-FLT is not incorporated into DNA, as shown by the dotted arrow. Abbreviations: ENT, Equilibrative Nucleoside Transporter; TMP, Thymidine Monophosphate; TDP, Thymidine Diphosphate; TTP, Thymidine Triphospate; dNT, deoxyribonucleotidase.
Table 1.
Patient demographics and characteristics.
Table 2.
Results of standardized uptake value, non linear regression and Patlak Ki analysis per scan.
Figure 2.
Correlation between SUV and Patlak at baseline and 4 hours after pemetrexed administration.
Table 3.
Plasma to blood ratio and parent fraction per scan.
Figure 3.
Example of 18F-FLT uptake (A) before and (B) 4 hours after pemetrexed administration, showing an increase of 18F-FLT uptake in the primary tumor (arrow) of 32% after pemetrexed administration.
Figure 4.
Change of 18F-FLT uptake in SUV 40–60 min normalised to bodyweight (A) absolute difference, (B) percentage difference.
Figure 5.
Mean SUV in muscle, liver, bone marrow and lung.
Mean SUV normalised to bodyweight for muscle, liver, bone marrow and lung at baseline and 4 hours after pemetrexed.
Table 4.
Study results per patient.
Figure 6.
Box plots with absolute differences in SUV.
SUV 40–60 min normalised to bodyweight for (A) tumor response after 6 weeks, (B) immunohistochemistry thymidylate synthase expression, (C) thymidylate synthase polymorphism, (D) methylenetetrahydrofolate reductase polymorphism.
Figure 7.
Plasma deoxyuridine over time.
*Significant differences tested with paired t-test, p<0.05, indicated by the accolade.
Figure 8.
Thymidilate synthase immunohistochemistry (20 ×).
In (A) scattered nuclear staining in >50% nuclei, and in (B) around 10% of the nuclei. Note in (A) also concomitant scattered cytoplasmic staining.